NASDAQ:ELOX Eloxx Pharmaceuticals (ELOX) Stock Price, News & Analysis $15.42 +0.42 (+2.80%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsSEC Filings About Eloxx Pharmaceuticals Stock (NASDAQ:ELOX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Eloxx Pharmaceuticals alerts:Sign Up Key Stats Today's Range$14.79▼$15.4550-Day Range$11.94▼$20.9852-Week Range$8.20▼$23.40Volume6,077 shsAverage Volume48,865 shsMarket Capitalization$62.30 millionP/E RatioN/ADividend YieldN/APrice Target$38.33Consensus RatingBuy Company Overview Eloxx Pharmaceuticals, Inc. was a clinical-stage biopharmaceutical company focused on developing therapies for genetic diseases caused by nonsense mutations, which can prevent cells from producing functional proteins. The company’s research platform centered on ribosome modulation, an approach intended to encourage cells to read through certain premature stop signals in genetic instructions. Its lead product candidate, ELX-02, was an investigational small-molecule therapy designed to promote the production of full-length proteins in diseases associated with nonsense mutations. Eloxx evaluated ELX-02 primarily for cystinosis, a rare inherited disorder caused by mutations in the CTNS gene, and also explored potential applications in other genetic conditions, including cystic fibrosis. The company was formerly known as Zikani Therapeutics and conducted research and development activities in the United States and Israel, including work through its Israeli operations. Eloxx was a development-stage company and did not have an established portfolio of marketed products. Public information about its later operations and leadership is limited, and the company’s status changed substantially after its development programs were advanced.AI Generated. May Contain Errors. Read More Eloxx Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreELOX MarketRank™: Eloxx Pharmaceuticals scored higher than 58% of companies evaluated by MarketBeat, and ranked 384th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingEloxx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialEloxx Pharmaceuticals has a consensus price target of $38.33, representing about 148.6% upside from its current price of $15.42.Amount of Analyst CoverageEloxx Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Eloxx Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Eloxx Pharmaceuticals is -10.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eloxx Pharmaceuticals is -10.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.53% of the float of Eloxx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEloxx Pharmaceuticals has a short interest ratio ("days to cover") of 1.38, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eloxx Pharmaceuticals has recently increased by 58.26%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEloxx Pharmaceuticals does not currently pay a dividend.Dividend GrowthEloxx Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment0.10 News SentimentEloxx Pharmaceuticals has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Eloxx Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for ELOX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eloxx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders25.90% of the stock of Eloxx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions2.90% of the stock of Eloxx Pharmaceuticals is held by institutions.Read more about Eloxx Pharmaceuticals' insider trading history. Receive ELOX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eloxx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELOX Stock News HeadlinesComparing Eloxx Pharmaceuticals (ELOX) & Its PeersSeptember 29 at 3:59 AM | americanbankingnews.comContrasting Eloxx Pharmaceuticals (ELOX) and Its PeersSeptember 28 at 5:15 AM | americanbankingnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.September 29 at 1:00 AM | Chaikin Analytics (Ad)Eloxx Pharmaceuticals (ELOX) and Its Competitors Head-To-Head ContrastSeptember 26 at 3:59 AM | americanbankingnews.comEloxx Pharmaceuticals (ELOX) and Its Peers Financial ContrastSeptember 25, 2026 | americanbankingnews.comEloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Receives Consensus Rating of "Buy" from AnalystsSeptember 23, 2026 | americanbankingnews.comEloxx Pharmaceuticals (ELOX) vs. Its Peers Financial AnalysisSeptember 21, 2026 | americanbankingnews.comEloxx Pharmaceuticals (ELOX) & Its Rivals Financial ComparisonSeptember 21, 2026 | americanbankingnews.comSee More Headlines ELOX Stock Analysis - Frequently Asked Questions How have ELOX shares performed this year? Eloxx Pharmaceuticals' stock was trading at $0.0121 on January 22, 2026. Since then, ELOX shares have increased by 127,338.0% and is now trading at $15.42. How were Eloxx Pharmaceuticals' earnings last quarter? Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) issued its earnings results on Tuesday, August, 11th. The company reported ($0.66) earnings per share for the quarter. When did Eloxx Pharmaceuticals' stock split? Eloxx Pharmaceuticals's stock reverse split on Monday, June 1st 2026.A 1-11 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 29th 2026. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split. When did Eloxx Pharmaceuticals IPO? Eloxx Pharmaceuticals (ELOX) raised $33 million in an initial public offering (IPO) on Tuesday, June 9th 2026. The company issued 2,975,000 shares at a price of $11.00 per share. How do I buy shares of Eloxx Pharmaceuticals? Shares of ELOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/11/2026Today9/29/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ELOX CIK1035354 Webwww.eloxxpharma.com Phone781-577-5300Fax908-864-4440Employees7Year FoundedN/APrice Target and Rating Average Price Target for Eloxx Pharmaceuticals$38.33 High Price Target$43.00 Low Price Target$32.00 Potential Upside/Downside+148.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.74 Quick Ratio3.74 Sales & Book Value Annual Sales$6.36 million Price / Sales9.80 Cash FlowN/A Price / Cash FlowN/A Book Value($85.17) per share Price / Book-0.18Miscellaneous Outstanding Shares4,040,000Free Float2,991,000Market Cap$62.30 million OptionableN/A Beta-1,862.26 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ELOX) was last updated on 9/29/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eloxx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eloxx Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
